Salvador Sierra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8501965/publications.pdf Version: 2024-02-01



SALVADOD SIEDDA

#	Article	IF	CITATIONS
1	Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice. Neuropharmacology, 2022, 209, 108988.	2.0	7
2	Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice. ACS Chemical Neuroscience, 2021, 12, 831-844.	1.7	14
3	Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Reports, 2021, 37, 109836.	2.9	82
4	Class A GPCR oligomerization. , 2020, , 121-140.		1
5	Autoantibodies Blocking <scp>M₃</scp> Muscarinic Receptors Cause Postganglionic Cholinergic Dysautonomia. Annals of Neurology, 2020, 88, 1237-1243.	2.8	8
6	Biased signaling by endogenous opioid peptides. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11820-11828.	3.3	78
7	Adjunctive effect of the serotonin 5-HT2C receptor agonist lorcaserin on opioid-induced antinociception in mice. Neuropharmacology, 2020, 167, 107949.	2.0	11
8	Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain. ACS Pharmacology and Translational Science, 2019, 2, 219-229.	2.5	32
9	The endocannabinoid system in cardiovascular function: novel insights and clinical implications. Clinical Autonomic Research, 2018, 28, 35-52.	1.4	43
10	Class A GPCRs: Cannabinoid and Opioid Receptor Heteromers. , 2017, , 173-206.		1
11	Is biological aging accelerated in drug addiction?. Current Opinion in Behavioral Sciences, 2017, 13, 34-39.	2.0	70
12	Detection of Receptor Heteromerization Using In Situ Proximity Ligation Assay. Current Protocols in Pharmacology, 2016, 75, 2.16.1-2.16.31.	4.0	47
13	Identification of GPR83 as the receptor for the neuroendocrine peptide PEN. Science Signaling, 2016, 9, ra43.	1.6	66
14	Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain Structure and Function, 2015, 220, 2721-2738.	1.2	82
15	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. Drugs and Aging, 2015, 32, 401-407.	1.3	18
16	Lethal leukoencephalopathy secondary to Tegafur, a 5-fluorouracil prodrug. Journal of the Neurological Sciences, 2015, 357, 326-328.	0.3	4
17	Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Frontiers in Neuroanatomy, 2014, 8, 146.	0.9	45
18	l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology, 2014, 79, 90-100.	2.0	83

SALVADOR SIERRA

#	Article	IF	CITATIONS
19	CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Experimental Neurology, 2014, 261, 44-52.	2.0	73
20	Choroid Plexitis as a Unique Neurological Manifestation in Granulomatosis with Polyangiitis (Wegener's Disease). Journal of Rheumatology, 2014, 41, 1192-1193.	1.0	2
21	Unmasking adenosine 2A receptors (A2ARs) in monkey basal ganglia output neurons using cholera toxin subunit B (CTB). Neurobiology of Disease, 2012, 47, 347-357.	2.1	4
22	Analysis of the pain in multiple sclerosis patients. NeurologÃa (English Edition), 2011, 26, 208-213.	0.2	18
23	Análisis del dolor en pacientes con esclerosis múltiple. NeurologÃa, 2011, 26, 208-213.	0.3	45
24	Glutamatergic and cholinergic pedunculopontine neurons innervate the thalamic parafascicular nucleus in rats: changes following experimental parkinsonism. Brain Structure and Function, 2011, 216, 319-330.	1.2	24
25	Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys. Brain Structure and Function, 2011, 216, 371-386.	1.2	6